

AT A GLANCE:

Active PAH & PH-ILD Studies Enrolling at the Temple Lung Center

Use this quick-reference guide to identify which patients may qualify for referral. For more information about these research trials, email [breathebetter@tuhs.temple.edu](mailto:breathebetter@tuhs.temple.edu) or call **215-707-1359**.

|                           | ALLROCK                                                                                                                                                                                                       | INSMED 311                                                                                                                                                       | INSMED 301                                                                                                                                                                       | MOMENTOUS                                                                                                                                                     |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DISEASE                   | WHO Group 1 PAH<br>WHO Group 3 ILD-PH                                                                                                                                                                         | WHO Group 3 ILD-PH                                                                                                                                               | WHO Group 1 PAH                                                                                                                                                                  | A known diagnosis of interstitial lung disease<br><b>Exclusion:</b> A known diagnosis of pulmonary hypertension/PAH                                           |
| AGE                       | >=18 years and <=80 years                                                                                                                                                                                     | >= 18 years                                                                                                                                                      | >=18 years and <= 75 years                                                                                                                                                       | >= 18 years                                                                                                                                                   |
| MEDS                      | WHO Group 1 <b>PAH:</b> at least 1 approved PAH medication (Cohort 2: sotatercept)<br>WHO Group 3 <b>ILD-PH: ONLY</b> inhaled Treprostinil and/or PDE5i                                                       | <b>Exclusion:</b> Use of PAH-approved therapy or any PH-ILD approved Treprostinil therapy w/in 30 days of screening<br><b>PDE5i allowed AND</b> on >= 90 days    | Stable PAH therapy <b>consisting of 1 to 3 medications:</b><br>ERA's, PDE5i, sGC Stimulator, Activin signaling inhibitor                                                         | <b>Exclusion:</b> Use of PAH-approved therapy or any PH-ILD approved Treprostinil therapy w/in 30 days of screening<br><b>PDE5i allowed AND</b> on >= 90 days |
| NYHA/WHO Functional Class | Class II or III                                                                                                                                                                                               | N/A                                                                                                                                                              | Class II, III, IV                                                                                                                                                                | N/A                                                                                                                                                           |
| CT SCAN                   | <b>WHO Group 3 ILD-PH:</b><br>> than 10% fibrosis on HRCT and < 10% emphysema                                                                                                                                 | Confirmation of fibrotic ILD<br>(Performed at screening or w/in 12 mos.)                                                                                         | N/A                                                                                                                                                                              | N/A                                                                                                                                                           |
| 6MWD                      | >= 100 and <= 550 meters                                                                                                                                                                                      | >= 100 and <= 500 meters                                                                                                                                         | >= 150 and <= 450 meters                                                                                                                                                         | N/A                                                                                                                                                           |
| PFT's                     | <ul style="list-style-type: none"><li><b>PAH:</b> FVC &gt; 70% predicted<br/>FEV1/FVC&gt; 0.70 predicted</li><li><b>ILD-PH:</b> FEV1/FVC &gt; 65%, FVC &gt; 50%<br/>DLCO (corrected for Hgb)&gt;25%</li></ul> | <b>Exclusion:</b><br>Primary COPD dx <b>and/or</b> FEV1/FVC < 0.7<br>(Screening or historical w/in 6 mos.)                                                       | <b>Exclusion:</b> <ul style="list-style-type: none"><li>FEV1/FVC &lt;0.7</li><li>FVC&lt; 70% pred.</li></ul> (Screening or historical w/in 6 mos.)                               | <ul style="list-style-type: none"><li>Performed as SOC within 6 months prior to consent</li><li>DLCO &lt; 80% predicted</li></ul>                             |
| ECHO                      | <b>Exclusion: LVEF &lt;50%;</b> grade 2 of more diastolic dysfx; >= 2+ (or > mild) mitral or aortic regurgitation                                                                                             | <b>Exclusion: LVEF &lt;45%;</b> clinically significant L-sided valvular heart disease, postcapillary PH                                                          | <b>Exclusion: LVEF &lt;45%;</b> clinically significant L-sided valvular heart disease, postcapillary PH                                                                          | LV ejection fraction ≤ 40%                                                                                                                                    |
| RHC                       | <ul style="list-style-type: none"><li><b>PAH:</b> PVR &gt;= 5wu, PCWP &lt;=15, mPAP &gt;20</li><li><b>ILD-PH:</b> PVR &gt;= 3wu, PCWP &lt;=15, mPAP &gt; 20</li></ul> (w/in 2 weeks of or during Screening)   | <ul style="list-style-type: none"><li>PVR &gt;= 4 wood units</li><li>PCWP &lt;= 15 mmHg</li><li>mPAP &gt; 20 mmHg</li></ul> (at Screening or w/in 12 mos. prior) | <ul style="list-style-type: none"><li>PVR &gt;= 5 wood units</li><li>PCWP or LVEDP &lt;= 15 mmHg</li><li>mPAP &gt; 20 mmHg at rest</li></ul> (at Screening or w/in 6 mos. prior) | <b>Exclusion:</b> A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent                                      |
| EKG                       | <ul style="list-style-type: none"><li><b>QTcF</b> interval &lt;= 450 (m) &lt;= 460 (f)</li><li>QRS interval &lt;= 120 msec</li><li>NSR between 40-100 bpm</li></ul>                                           | <b>QTcF</b> interval >500 ms<br><b>Exclusion:</b> Unstable arrhythmia including uncontrolled Atrial Fibrillation                                                 | <b>QTcF</b> interval >>450 ms (m) or >470 ms (f)<br><b>Exclusion:</b> Unstable arrhythmia including uncontrolled Atrial Fibrillation                                             | Done on study using AI model to predict PH/PAH                                                                                                                |